Your browser is no longer supported. Please, upgrade your browser.
FTSV Forty Seven, Inc. daily Stock Chart
FTSV [NASD]
Forty Seven, Inc.
Index- P/E- EPS (ttm)-2.78 Insider Own2.30% Shs Outstand45.45M Perf Week2.33%
Market Cap2.07B Forward P/E- EPS next Y-2.78 Insider Trans-16.40% Shs Float40.59M Perf Month10.94%
Income-78.60M PEG- EPS next Q-0.71 Inst Own65.70% Short Float4.31% Perf Quarter338.52%
Sales15.70M P/S132.15 EPS this Y-163.60% Inst Trans0.40% Short Ratio1.98 Perf Half Y613.28%
Book/sh3.98 P/B11.47 EPS next Y-9.40% ROA-54.30% Target Price48.00 Perf Year194.90%
Cash/sh3.67 P/C12.44 EPS next 5Y- ROE-63.40% 52W Range5.53 - 49.50 Perf YTD15.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.78% Beta-
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low725.50% ATR3.47
Employees62 Current Ratio7.50 Sales Q/Q- Oper. Margin- RSI (14)62.18 Volatility9.09% 9.36%
OptionableYes Debt/Eq0.00 EPS Q/Q45.30% Profit Margin- Rel Volume0.62 Prev Close44.81
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume881.10K Price45.65
Recom1.80 SMA209.50% SMA5019.72% SMA200174.28% Volume547,985 Change1.87%
Jan-13-20Initiated SunTrust Buy $55
Nov-20-19Resumed Guggenheim Buy
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $28
Apr-12-19Initiated Guggenheim Buy
Dec-21-18Initiated BTIG Research Buy
Nov-30-18Initiated H.C. Wainwright Buy $21
Feb-17-20 10:06AM  3 Stocks That Are Way More Expensive Than Tesla GuruFocus.com
Feb-06-20 08:00AM  Forty Seven to Present at Upcoming Investor Conferences in February GlobeNewswire
Feb-04-20 05:09AM  Introducing Forty Seven (NASDAQ:FTSV), The Stock That Zoomed 178% In The Last Year Simply Wall St.
Jan-10-20 06:04PM  Analysts: The 5 Top Stocks Youll Want to Own In 2020 TipRanks
08:00AM  Forty Seven Announces 2020 Strategic Priorities and Expected Milestones GlobeNewswire
Dec-26-19 07:55AM  The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares Benzinga
Dec-18-19 07:05AM  2 Strong Buy Stocks That Credit Suisse Expects to Soar TipRanks
Dec-17-19 05:45PM  Do Hedge Funds Love Forty Seven, Inc. (FTSV)? Insider Monkey
Dec-16-19 04:01PM  Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares GlobeNewswire
Dec-12-19 07:38AM  The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win Benzinga +7.73%
Dec-11-19 10:32PM  Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock GlobeNewswire
04:01PM  Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Dec-09-19 10:00AM  Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation GlobeNewswire +110.73%
07:00AM  Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia GlobeNewswire
Nov-14-19 01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
Nov-12-19 07:01AM  Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire +12.87%
Nov-07-19 03:07PM  Here is What Hedge Funds Think About Forty Seven, Inc. (FTSV) Insider Monkey
Nov-06-19 09:01AM  Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting GlobeNewswire +17.62%
06:31AM  Here's Why We're Watching Forty Seven's (NASDAQ:FTSV) Cash Burn Situation Simply Wall St.
Nov-05-19 08:01AM  Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Sep-27-19 08:01AM  Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-03-19 04:01PM  Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire -8.18%
08:01AM  Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia GlobeNewswire
Aug-14-19 04:07PM  Forty Seven, Inc. (FTSV) Q2 Earnings Call Transcript Motley Fool -18.98%
03:40PM  Its not just Bloom Energy: Half of last years Bay Area IPO stocks are underwater American City Business Journals
Aug-13-19 04:01PM  Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Aug-06-19 08:01AM  Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome GlobeNewswire
Jul-31-19 08:01AM  Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-29-19 08:08AM  3 Biotech Stocks Corporate Insiders are Buying TipRanks
Jul-26-19 01:11PM  Insiders Roundup: Garmin, Best Buy GuruFocus.com
Jul-22-19 04:01PM  Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares GlobeNewswire
Jul-17-19 07:15PM  Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock GlobeNewswire -13.44%
Jul-16-19 04:01PM  Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Jul-11-19 10:42AM  Forty Seven Wins Exclusive License Deal For 5F9 Benzinga
08:35AM  Have Insiders Been Buying Forty Seven, Inc. (NASDAQ:FTSV) Shares? Simply Wall St.
07:00AM  Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia GlobeNewswire
Jun-15-19 09:00AM  Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkins Lymphoma GlobeNewswire
Jun-03-19 08:00AM  Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia GlobeNewswire
May-16-19 09:01AM  Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkins Lymphoma at 24th Congress of the European Hematology Association GlobeNewswire -19.14%
May-15-19 05:01PM  Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting GlobeNewswire
May-14-19 12:29AM  Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript Motley Fool -9.79%
May-13-19 04:01PM  Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Forty Seven, Inc. to Host Earnings Call ACCESSWIRE
May-09-19 08:10PM  Were Hedge Funds Right About Dumping Forty Seven, Inc. (FTSV)? Insider Monkey
May-06-19 04:05PM  Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019 GlobeNewswire
Apr-26-19 08:01AM  Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkins Lymphoma GlobeNewswire
Apr-25-19 10:11AM  Top Ranked Momentum Stocks to Buy for April 25th Zacks
Mar-30-19 10:24AM  Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price? Simply Wall St.
Mar-28-19 04:05PM  Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Forty Seven Inc to Host Earnings Call ACCESSWIRE
Mar-21-19 04:01PM  Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019 GlobeNewswire
Mar-12-19 08:00AM  Forty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare Conference GlobeNewswire
Feb-12-19 05:25PM  Health Care Digest: Salesforce's DNA leads deeper into health, a defiant cancer startup and more American City Business Journals
Feb-07-19 08:00AM  Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day GlobeNewswire -5.34%
Jan-15-19 08:00AM  Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019 GlobeNewswire
Jan-07-19 08:00AM  Forty Seven Inc. Announces 2019 Strategic Priorities and Expected Milestones GlobeNewswire
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
Dec-21-18 11:50AM  Should You Take Comfort From Insider Transactions At Forty Seven, Inc. (NASDAQ:FTSV)? Simply Wall St.
Nov-13-18 08:00AM  Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Nov-07-18 08:00AM  Forty Seven Inc. to Present at the Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Nov-01-18 09:00AM  Forty Seven Inc. to Present New Preclinical Data on 5F9 at the 60th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-31-18 05:00PM  Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkins Lymphoma (NHL) GlobeNewswire
Oct-03-18 08:00AM  Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB) GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals
Sep-06-18 08:00AM  Forty Seven Inc. to Present at the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-13-18 04:01PM  Forty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Aug-02-18 08:00AM  Forty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-23-18 03:21PM  Morgan Stanley, Canaccord Genuity Out Bullish On Forty Seven: 'A Significant Lead' Benzinga
Jul-19-18 11:30AM  Foresight Solar & Infrastructure VCT plc - Transaction in own shares GlobeNewswire
Jul-13-18 02:45PM  Here are Q2's 10 biggest VC-backed exits from the Bay Area American City Business Journals
Jul-03-18 11:30AM  Foresight Solar & Infrastructure VCT plc - Transaction in own shares GlobeNewswire
Jul-02-18 07:30AM  [$$] Biotech Companies Continue IPO Hot Streak, But For How Long? The Wall Street Journal
Jun-29-18 12:15PM  Foresight Solar & Infrastructure VCT plc - GM Statement and Share Class Merger GlobeNewswire +6.31%
Jun-27-18 09:56PM  Forty Seven Prices Initial Public Offering GlobeNewswire
Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven, Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven, Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Majeti RavindraDirectorJan 15Sale36.3525,000908,6981,086,400Jan 16 09:21 PM
WEISSMAN IRVINGDirectorDec 26Sale44.2230,0001,326,6812,002,761Dec 30 05:56 PM
Majeti RavindraDirectorDec 16Sale35.4925,000887,1681,111,400Dec 17 07:29 PM
Takimoto Chris HChief Medical OfficerDec 10Option Exercise2.0210,00020,15010,000Dec 11 09:57 PM
Takimoto Chris HChief Medical OfficerDec 10Sale35.0010,000350,0000Dec 11 09:57 PM
Takimoto Chris HChief Medical OfficerDec 09Option Exercise2.0210,00020,15010,000Dec 10 09:53 PM
Takimoto Chris HChief Medical OfficerDec 09Sale30.0010,000300,0000Dec 10 09:53 PM
WEISSMAN IRVINGDirectorDec 09Sale16.2220,000324,4092,032,761Dec 10 09:52 PM
Majeti RavindraDirectorDec 09Sale19.6265,0001,275,0001,136,400Dec 10 09:51 PM
Majeti RavindraDirectorNov 20Sale12.505,00062,5001,201,400Nov 22 06:57 PM
Majeti RavindraDirectorNov 18Sale10.2615,000153,9151,206,400Nov 20 08:01 PM